In a diverse group of patients with active RA, addition of CZP to current therapy for up to 28 weeks was associated with sustained improvements in disease activity and physical function as measured by a variety of clinical endpoints, including ACR20/ACR50/ACR70 response rates, DAS28(ESR), DAS28(CRP), and HAQ-DI. The gene discussed is CRP; the disease is rheumatoid arthritis.